Data Availability
Data will be available upon request from the corresponding author.
References
Fiore A, et al. Deubiquitinase mysm1 in the hematopoietic system and beyond: A current review. Int J Mol Sci. 2020;21(8):1–15. https://doi.org/10.3390/ijms21083007.
Alsultan A, Shamseldin HE, Osman ME, Aljabri M, Alkuraya FS. MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts. Blood. 2013;122(23):3844–5. https://doi.org/10.1182/blood-2013-09-527127.
Le Guen T, et al. An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation. J Allergy Clin Immunol. 2015;136(6):1619-1626.e5. https://doi.org/10.1016/j.jaci.2015.06.008.
Bahrami E, et al. Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations. J Allergy Clin Immunol. 2017;140(4):1112–9. https://doi.org/10.1016/j.jaci.2016.10.053.
Barhoom D, Mohseni R, Behfar M, Hamidieh AA. Successful allogeneic stem cell transplantation with fludarabine-based reduced intensity conditioning in bone marrow failure syndrome 4. Pediatr Transplant. 2021;25(7):4–7. https://doi.org/10.1111/petr.14089.
Acknowledgements
We thank the members of the primary immunodeficiency (PID)_team in Belarus:
Aleshkevich Svetlana N.1, Pakhomava Iryna V.1, Belobokova Victoria D.1, Poliakova Ekaterina A.1, Volodashchik Tatiana P.1, Migas Alexandr A.1, Kupchinskaya Aleksandra N.1, Shman Tatsiana V.1, Mikhaleuskaya Taisiya M.1, Belevtsev Mikhail V.1, Proleskovskaya Inna V.1, Demidchik Valeria7
1 – Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk region, Belarus
7 – N.N Alexandrov Cancer Centre of Belarus, Minsk region, Belarus
We thank Joseph Dasso for editing this manuscript, primarily for proper English.
Funding
This research received no external funding support.
Author information
Authors and Affiliations
Consortia
Contributions
ASN, PIV and DV managed the patient and half-sister. HE and SJ performed WES. SIS, PIV, BVD, PEA, VTP, MAA, KAN, STV, MTM and BMV performed in vitro analyses. Manuscript were written by SIS and edited by SJ and SSO. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval
This study has been approved by the ethics committee of the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus. Biological material was sampled after signing of informed consent in accordance with the Declaration of Helsinki.
Consent to Participate
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
The authors affirm that patient provided informed consent for publication of all images in Fig. 5S.
Conflicts of Interest/Competing Interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sakovich, I.S., Haapaniemi, E., PID_team_Belarus. et al. Clinical Course and Family History of Adult Patient with Novel MYSM1 Variant. J Clin Immunol 44, 9 (2024). https://doi.org/10.1007/s10875-023-01609-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10875-023-01609-1